Literature DB >> 12648230

Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression.

Marzia Pennati1, Mara Binda, Gennaro Colella, Marco Folini, Lorenzo Citti, Raffaella Villa, Maria Grazia Daidone, Nadia Zaffaroni.   

Abstract

Survivin is a structurally unique member of the inhibitors of apoptosis protein family and is involved in the control of cell division and inhibition of apoptosis. The notion that survivin is overexpressed in most human tumors but absent in normal adult tissues with only a few exceptions has led to the proposal of survivin as a promising therapeutic target for novel anticancer therapies. In this context, we generated a hammerhead ribozyme targeting the 3' end of the CUA110 triplet in the survivin mRNA. Two human melanoma cell lines (JR8 and M14) overexpressing survivin were stably transfected with the pRc/CMV vector carrying the ribozyme sequence. Two polyclonal cell populations proven to endogenously express ribozyme and characterized by a markedly lower survivin protein level (-60% and -50%, respectively) than JR8 and M14 parental cells were selected for the study. Ribozyme-expressing cells showed a significantly (p<0.01) increased sensitivity to gamma-irradiation (as detected by clonogenic cell survival) compared to JR8 and M14 cells. Moreover, in the JR8 cell line, the extent of radiation-induced apoptosis (in terms of percentage of apoptotic nuclei in cells stained with propidium iodide and level of caspase-3 catalytic activity) was markedly greater in ribozyme-expressing cells than in parental cells. These results demonstrate for the first time that attenuation of survivin expression renders human melanoma cells more susceptible to gamma-irradiation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12648230     DOI: 10.1046/j.1523-1747.2003.12082.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  20 in total

1.  The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin.

Authors:  Anjaiah Srirangam; Monica Milani; Ranjana Mitra; Zhijun Guo; Mariangellys Rodriguez; Hitesh Kathuria; Seiji Fukuda; Anthony Rizzardi; Stephen Schmechel; David G Skalnik; Louis M Pelus; David A Potter
Journal:  J Thorac Oncol       Date:  2011-04       Impact factor: 15.609

Review 2.  Survivin and leukemia.

Authors:  Xiu Li Cong; Zhong Chao Han
Journal:  Int J Hematol       Date:  2004-10       Impact factor: 2.490

Review 3.  ErbB receptors: from oncogenes to targeted cancer therapies.

Authors:  Hongtao Zhang; Alan Berezov; Qiang Wang; Geng Zhang; Jeffrey Drebin; Ramachandran Murali; Mark I Greene
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

4.  Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity.

Authors:  Jianguo Wu; Xiang Ling; Dalin Pan; Pasha Apontes; Lei Song; Ping Liang; Dario C Altieri; Terry Beerman; Fengzhi Li
Journal:  J Biol Chem       Date:  2005-01-05       Impact factor: 5.157

5.  Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA.

Authors:  Songchuan Guo; Nuska Tschammer; Sulma Mohammed; Peixuan Guo
Journal:  Hum Gene Ther       Date:  2005-09       Impact factor: 5.695

6.  siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity.

Authors:  Wen-Song Liu; Hai-Jiao Yan; Ren-Yi Qin; Rui Tian; Min Wang; Jian-Xin Jiang; Ming Shen; Cheng-Jian Shi
Journal:  Dig Dis Sci       Date:  2008-07-02       Impact factor: 3.199

7.  Experience with peritoneal mesothelioma at the Milan National Cancer Institute.

Authors:  Marcello Deraco; Dario Baratti; Antonello Domenico Cabras; Nadia Zaffaroni; Federica Perrone; Raffaella Villa; Jenny Jocollè; Maria Rosaria Balestra; Shigeki Kusamura; Barbara Laterza; Silvana Pilotti
Journal:  World J Gastrointest Oncol       Date:  2010-02-15

8.  Survivin expression induced by doxorubicin in cholangiocarcinoma.

Authors:  Qing Chang; Zheng-Ren Liu; Da-Yu Wang; Manoj Kumar; Yi-Bei Chen; Ren-Yi Qin
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

Review 9.  Survivin: potential role in diagnosis, prognosis and targeted therapy of gastric cancer.

Authors:  Ting-Ting Wang; Xiao-Ping Qian; Bao-Rui Liu
Journal:  World J Gastroenterol       Date:  2007-05-28       Impact factor: 5.742

10.  Enhanced antitumor effect of combined gemcitabine and proton radiation in the treatment of pancreatic cancer.

Authors:  Nicholas R Galloway; Jonathan R Aspe; Chelsey Sellers; Nathan R Wall
Journal:  Pancreas       Date:  2009-10       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.